Q2 Earnings Forecast for AC Immune Issued By Leerink Partnrs

AC Immune SA (NASDAQ:ACIU) – Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of AC Immune in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman anticipates that the company will post earnings of ($0.17) per share for the quarter. The consensus estimate for AC Immune’s current full-year earnings is ($0.62) per share. Leerink Partnrs also issued estimates for AC Immune’s Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.85) EPS and FY2026 earnings at ($0.60) EPS.

Separately, HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research note on Thursday, April 3rd.

AC Immune Price Performance

Shares of AC Immune stock opened at $1.51 on Wednesday. The stock has a market capitalization of $151.62 million, a PE ratio of -3.28 and a beta of 1.49. AC Immune has a 1-year low of $1.43 and a 1-year high of $4.98. The company’s fifty day simple moving average is $2.18 and its 200-day simple moving average is $2.73.

Hedge Funds Weigh In On AC Immune

Several institutional investors have recently bought and sold shares of ACIU. Northern Trust Corp purchased a new position in AC Immune in the fourth quarter worth about $1,088,000. Renaissance Technologies LLC increased its position in shares of AC Immune by 14.6% during the 4th quarter. Renaissance Technologies LLC now owns 740,198 shares of the company’s stock valued at $1,999,000 after purchasing an additional 94,191 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in AC Immune by 130.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock valued at $355,000 after buying an additional 74,358 shares during the period. Squarepoint Ops LLC purchased a new position in AC Immune during the fourth quarter worth $118,000. Finally, Cantor Fitzgerald L. P. purchased a new stake in shares of AC Immune in the fourth quarter valued at $68,000. Institutional investors own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.